Global Leber Congenital Amaurosis - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 30+ Markets) - 2026 To 2036

Global Leber Congenital Amaurosis Market Outlook and Forecast

Thelansis's "Global Leber Congenital Amaurosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 30+ Markets) - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leber Congenital Amaurosis treatment modalities options for the 30+ markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Leber Congenital Amaurosis Overview

Leber congenital amaurosis (LCA) is a genetically diverse group of early-onset retinal dystrophies, usually presenting in infancy with severe visual loss, nystagmus, sluggish pupils and photophobia. Variants in CEP290, GUCY2D, RPE65 and CRB1 disrupt retinal function; inheritance is usually autosomal recessive, and severity varies. Care includes low-vision rehabilitation, educational support and genetic counselling. Voretigene neparvovec (Luxturna) is approved for confirmed biallelic RPE65-associated retinal dystrophy in patients with viable retinal cells, benefiting a defined subset. Other approaches are genotype-specific: ATSN-101, an AAV gene therapy for GUCY2D-LCA, is in Phase I/II testing; sepofarsen, an antisense oligonucleotide for a CEP290 variant, is in Phase III; EDIT-101, a CRISPR-Cas9 treatment for the same variant, showed early proof of concept, but enrolment was paused in 2022. Genetic heterogeneity, photoreceptor loss, ocular delivery and durability remain key challenges.

Key Highlights

• In the United States, LCA prevalence cases are projected to increase from 59,596 in 2026 to 65,506 by 2036.
• LCA is a rare inherited retinal disorder causing severe visual impairment from early childhood.
• Progressive vision loss and limited treatment options create a significant disease burden.
• Significant unmet need remains for therapies that preserve or restore vision.

Market Overview

• The Germany LCA market is projected to grow from $130M in 2026 to $200M by 2036.
• Market growth is driven by:
• Increasing adoption of gene therapy and emerging retinal therapies
• Advances in genetic diagnosis and disease understanding
• Future growth will depend on durable treatments that preserve or improve visual function.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 30+ markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

30 countries covered:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Opus Genetics, Inc.
• Spark Therapeutics, Inc.
• Ocugen
• Atsena Therapeutics Inc.